2018
DOI: 10.1007/s11664-018-6628-4
|View full text |Cite
|
Sign up to set email alerts
|

WOWS Sol–Gel Based Synthesis and Structural, Morphological, Electrical and Magnetic Characterization of Co-Sm Doped M-Type Barium Hexaferrite Materials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 22 publications
(3 citation statements)
references
References 47 publications
0
3
0
Order By: Relevance
“…The n-MASnI 3 and p-MASnI 3 layers were obtained by varying the MASnI 3 doping concentration of the absorber layer to replace the ETL and HTL. The designed device structure is FTO/n-MASnI 3 /i-MASnI 3 /p-MASnI 3 /Au, and considering the defects between the interfaces, 16 we set two interface defect layers (IDL1 and IDL2) between n-MASnI 3 /i-MASnI 3 and i-MASnI 3 /p-MASnI 3 , respectively. The structure diagram and energy band diagram of the device are shown in Figs.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The n-MASnI 3 and p-MASnI 3 layers were obtained by varying the MASnI 3 doping concentration of the absorber layer to replace the ETL and HTL. The designed device structure is FTO/n-MASnI 3 /i-MASnI 3 /p-MASnI 3 /Au, and considering the defects between the interfaces, 16 we set two interface defect layers (IDL1 and IDL2) between n-MASnI 3 /i-MASnI 3 and i-MASnI 3 /p-MASnI 3 , respectively. The structure diagram and energy band diagram of the device are shown in Figs.…”
Section: Methodsmentioning
confidence: 99%
“…The parameters of the device structure can be found through the reported literature and experimental results. Using SCAPS-1D we selected reasonable parameters for each layer of the device modeling, [16][17][18] as shown in Table I. The capture cross section of i-MASnI 3 and i-MASnI 3 interfacial defect layer defects 1 × 10 -15 cm 2 with a defect density of 1 × 10 18 cm −3 .…”
Section: Methodsmentioning
confidence: 99%
“…19 It has achieved great attention since the privileged framework is frequently observed as a bioactive component in commercially available medicines, for example, Floxan 2 (anti-inflammatory medicine), pyrazomycin 3 (anticancer), difenamizole 4 (anti-inflammatory drug), and deramaxx 5 (NSAID) (Figure 1). 22,23 It is also utilized in paint and photographic industries and in the development of heat resistant resins. 24 The corresponding 3-oxygenated derivative, pyrazolone 6, which has an additional keto-group, is the basic component in drugs such as metamizole sodium and phenylbutazone (both are non-steroidal anti-inflammatory medicines, generally used as powerful painkillers and fever reducers) ( Figure 1).…”
Section: Introductionmentioning
confidence: 99%